1. Benchmarking of FLUKA production cross sections of positron emission tomography isotopes for in-vivo range verification in hadron therapy
- Author
-
Alfredo Ferrari, Giulia Aricò, Felix Horst, Francesco Cerutti, U. Weber, Giuseppe Battistoni, Christoph Schuy, and Andrea Mairani
- Subjects
Materials science ,Proton ,Quantitative Biology::Tissues and Organs ,QC1-999 ,medicine.medical_treatment ,Physics::Medical Physics ,chemistry.chemical_element ,01 natural sciences ,030218 nuclear medicine & medical imaging ,Ion ,Nuclear physics ,03 medical and health sciences ,0302 clinical medicine ,0103 physical sciences ,medicine ,Range (particle radiation) ,medicine.diagnostic_test ,Isotope ,010308 nuclear & particles physics ,Physics ,Radiation therapy ,chemistry ,Positron emission tomography ,Physics::Accelerator Physics ,Particle ,Carbon - Abstract
Protons and carbon ions have been extensively used for radiotherapy treatments, and in comparison to conventional radiotherapy, they allow a more conformal dose to the target tumor, especially in case of deep-seated tumors. However, the accuracy of hadron therapy treatments is affected by uncertainties in the particle range calculations. Several techniques are under development for in-vivo range verification, one of which consists on measuring the activity distributions of positron emitters, such as 10C, 11C and 15O, which are produced in the patient body during proton and carbon ion treatments. A comparison between measured and expected positron emitter activity distributions can provide information on the quality of the delivered treatment and accuracy of the particle range calculations. In this work the FLUKA production cross sections for 10C, 11C and 15O originated from proton and carbon ion beams in carbon and oxygen targets were compared with experimental data, at low and therapeutic energies.
- Published
- 2020
- Full Text
- View/download PDF